Loss of antiproliferative gene TOB1 results in more severe EAE driven by augmented pathogenic T cell responses. Reliable biomarkers corresponding to disease progression or therapeutic responsiveness in multiple sclerosis (MS) have not been yet identified. We previously reported that low expression of the antiproliferative gene TOB1 in CD4